SEARCH

SEARCH BY CITATION

References

  • 1
    Arellano ML,Langston A,Winton E, et al. Treatment of relapsed acute leukemia after allogeneic transplantation: A single center experience. Biol Blood Marrow Transplant 2007; 13: 116123.
  • 2
    Bethge WA,Storer BE,Maris MB, et al. Relapse or progression after hematopoietic cell transplantation using nonmyeloablative conditioning: Effect of interventions on outcome. Exp Hematol 2003; 31: 974980.
  • 3
    Collins RHJr,Shpilberg O,Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433444.
  • 4
    Frassoni F,Barrett AJ,Granena A, et al. Relapse after allogeneic bone marrow transplantation for acute leukaemia: A survey by the E.B.M.T. of 117 cases. Br J Haematol 1988; 70: 317320.
  • 5
    Mortimer J,Blinder MA,Schulman S, et al. Relapse of acute leukemia after marrow transplantation: Natural history and results of subsequent therapy. J Clin Oncol 1989; 7: 5057.
  • 6
    Oran B,Giralt S,Couriel D, et al. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia 2007; 21: 25402544.
  • 7
    Dazzi F,Fozza C. Disease relapse after haematopoietic stem cell transplantation: Risk factors and treatment. Baillieres Best Pract Res Clin Haematol 2007; 20: 311327.
  • 8
    Bosi A,Laszlo D,Labopin M, et al. Second allogeneic bone marrow transplantation in acute leukemia: Results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2001; 19: 36753684.
  • 9
    Eapen M,Giralt SA,Horowitz MM, et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 2004; 34: 721727.
  • 10
    Hosing C,Saliba RM,Shahjahan M, et al. Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transplant 2005; 36: 157162.
  • 11
    Michallet M,Tanguy ML,Socie G, et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: A survey of the Societe Francaise de Greffe de moelle (SFGM). Br J Haematol 2000; 108: 400407.
  • 12
    Mrsic M,Horowitz MM,Atkinson K, et al. Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant 1992; 9: 269275.
  • 13
    Radich JP,Sanders JE,Buckner CD, et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol 1993; 11: 304313.
  • 14
    Wagner JE,Vogelsang GB,Zehnbauer BA, et al. Relapse of leukemia after bone marrow transplantation: Effect of second myeloablative therapy. Bone Marrow Transplant 1992; 9: 205209.
  • 15
    Kishi K,Takahashi S,Gondo H, et al. Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: Results of a survey of 66 cases in 24 Japanese institutes. Bone Marrow Transplant 1997; 19: 461466.
  • 16
    Cheson BD,Bennett JM,Kopecky KJ, et al. Revised recommendations of the International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 46424649.
  • 17
    Saito K,Nakamura Y,Aoyagi M, et al. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol 2000; 71: 238244.
  • 18
    Yamada K,Furusawa S,Saito K, et al. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: A pilot study. Leukemia 1995; 9: 1014.
  • 19
    Pollyea DA,Artz AS,Stock W, et al. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2007; 40: 10271032.
  • 20
    Kolb HJ,Schmid C,Buhmann R, et al. DLI: Where are we know? Hematology 2005; 10( Suppl 1): 115116.
  • 21
    Kolb HJ,Schmid C,Weisser M, et al. Cytoreduction, DLI, or mobilized peripheral blood progenitors. Ann Hematol 2002; 81( Suppl 2): S30S33.
  • 22
    Mielcarek M,Storer BE,Flowers ME, et al. Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007; 13: 11601168.
  • 23
    Levine JE,Braun T,Penza SL, et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002; 20: 405412.
  • 24
    Barrett AJ,Locatelli F,Treleaven JG, et al. Second transplants for leukaemic relapse after bone marrow transplantation: High early mortality but favourable effect of chronic GVHD on continued remission. A report by the EBMT Leukaemia Working Party. Br J Haematol 1991; 79: 567574.